ATE447397T1 - Darreichungsform mit erhöhter bioverfügbarkeit - Google Patents

Darreichungsform mit erhöhter bioverfügbarkeit

Info

Publication number
ATE447397T1
ATE447397T1 AT04012901T AT04012901T ATE447397T1 AT E447397 T1 ATE447397 T1 AT E447397T1 AT 04012901 T AT04012901 T AT 04012901T AT 04012901 T AT04012901 T AT 04012901T AT E447397 T1 ATE447397 T1 AT E447397T1
Authority
AT
Austria
Prior art keywords
starch
composition
prepared
dosage form
bioavailability
Prior art date
Application number
AT04012901T
Other languages
English (en)
Inventor
Paolo C Trubiano
Afaf G Makarious
Original Assignee
Brunob Ii Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brunob Ii Bv filed Critical Brunob Ii Bv
Application granted granted Critical
Publication of ATE447397T1 publication Critical patent/ATE447397T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04012901T 2003-06-03 2004-06-01 Darreichungsform mit erhöhter bioverfügbarkeit ATE447397T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/453,011 US8252322B2 (en) 2003-06-03 2003-06-03 Delivery system with increased bioavailability

Publications (1)

Publication Number Publication Date
ATE447397T1 true ATE447397T1 (de) 2009-11-15

Family

ID=33159510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04012901T ATE447397T1 (de) 2003-06-03 2004-06-01 Darreichungsform mit erhöhter bioverfügbarkeit

Country Status (6)

Country Link
US (1) US8252322B2 (de)
EP (1) EP1484055B1 (de)
JP (2) JP4629368B2 (de)
AT (1) ATE447397T1 (de)
DE (1) DE602004023894D1 (de)
ES (1) ES2334664T3 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
WO2006063411A2 (en) * 2004-12-16 2006-06-22 Protech Research Pty Ltd Transfer of molecules
US7678399B2 (en) 2005-12-05 2010-03-16 Bunge Oils, Inc. Phytosterol containing deep-fried foods and methods with health promoting characteristics
ES2676284T3 (es) * 2006-02-06 2018-07-18 Dsm Ip Assets B.V. Composiciones de ingredientes activos
US10583098B2 (en) * 2006-05-02 2020-03-10 Sung Lan Hsia Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
JP4989956B2 (ja) * 2006-12-11 2012-08-01 松谷化学工業株式会社 粉末化植物ステロールエステル製剤、その製造方法及びこれを含む飲食品
EP1972324A1 (de) * 2007-03-21 2008-09-24 Cognis IP Management GmbH Verkapselte Liposomen
US20080286357A1 (en) * 2007-05-17 2008-11-20 Balchem Corporation Multi-functional particulate delivery system for pharmacologically active ingredients
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US20090197974A1 (en) * 2008-02-05 2009-08-06 Khaleeq Ahmed Natural dietary supplement tablet
WO2009126738A2 (en) * 2008-04-08 2009-10-15 Zymes, Llc Dried formulations
KR101072300B1 (ko) * 2009-01-13 2011-10-11 고려대학교 산학협력단 공액 리놀레인산 또는 그의 유도체를 함유하는 리포좀을 포함하는 사료 조성물
US20110124746A1 (en) * 2009-11-25 2011-05-26 National Starch & Chemical Company Alkenyl succinic acid anhydride half ester emulsifier
EP2884962B1 (de) * 2012-08-17 2019-05-01 Smartek International LLC Präparat aus entwässerten liposomen zur verwendung in komprimierbaren abgabesystemen
US8962092B2 (en) 2013-01-30 2015-02-24 Corn Products Development, Inc. Paper sizing using an agent containing uniformly bound octenyl succinic anhydride groups made by the reaction of octenyl succinic anhydride onto a dispersed waxy starch
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
PL3139904T3 (pl) 2014-05-05 2021-07-05 Basf Se Formulacja witaminy rozpuszczalnej w tłuszczach
CN104356245B (zh) * 2014-08-12 2017-02-01 齐鲁工业大学 一种酶变辛烯基琥珀酸酐淀粉在低温火腿保水性方面的应用
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10563243B2 (en) 2014-09-24 2020-02-18 Colgate-Palmolive Company Bioavailability of metal ions
EP3634391A4 (de) 2017-05-17 2021-02-24 Berg LLC Verwendung von coenzym-q10-formulierungen zur behandlung und vorbeugung von epidermolysis bullosa
EP3428195B1 (de) * 2017-07-10 2021-04-21 Corn Products Development, Inc. Modifizierte stärke
CA3096692A1 (en) * 2018-04-17 2019-10-24 Poviva Corp. Lipophilic active agent infused compositions with reduced food effect
WO2021222870A2 (en) * 2020-04-30 2021-11-04 Purser Danny C Superoxide dismutase compositions and methods
CN116983331B (zh) * 2023-09-07 2024-10-15 药大制药有限公司 一种儿童用比沙可啶脂质体的栓剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
CH661438A5 (it) * 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US4859377A (en) * 1987-07-10 1989-08-22 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of entomopathogens
US4985082A (en) 1987-11-20 1991-01-15 Lafayette Applied Chemistry, Inc. Microporous granular starch matrix compositions
US4977252A (en) 1988-03-11 1990-12-11 National Starch And Chemical Investment Holding Corporation Modified starch emulsifier characterized by shelf stability
US5185176A (en) 1988-03-11 1993-02-09 National Starch And Chemical Investment Holding Corporation Food products containing modified starch emulsifier
JP2540204B2 (ja) * 1988-08-18 1996-10-02 ナシヨナル・スターチ・アンド・ケミカル・コーポレイション 保存安定性を有する化工でんぷん乳化剤
US5492648A (en) 1993-07-02 1996-02-20 Lau; John R. Organic oil stabilization techniques
CA2241247C (en) 1995-12-15 2004-01-20 G. Dennis Sprott Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles
WO1998011877A1 (en) 1996-09-18 1998-03-26 Dragoco, Inc. Liposome encapsulated active agent dry powder composition
US6045823A (en) 1996-09-19 2000-04-04 Dragoco Gerberding & Co. Ag Process for producing solid anhydrous composition, and pharmaceutical and cosmetic products comprising same
WO1999011242A1 (en) * 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
EP0913406B1 (de) 1997-10-31 2004-07-07 National Starch and Chemical Investment Holding Corporation Mit Glukoamylase umgesetzte Stärkederivate und ihre Verwendung als Emulgatoren und Einkapselungsmittel
US6086917A (en) * 1998-10-23 2000-07-11 National Starch And Chemical Investment Holding Corporation Tablet containing an enzymatically converted starch derivative encapsulating agent
EP0922449B1 (de) 1997-10-31 2007-01-03 National Starch and Chemical Investment Holding Corporation Verwendung eines enzymatisch behandelten Stärkederivates als Einkapselungsmaterial
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation

Also Published As

Publication number Publication date
JP5313985B2 (ja) 2013-10-09
EP1484055A1 (de) 2004-12-08
DE602004023894D1 (de) 2009-12-17
US8252322B2 (en) 2012-08-28
US20040247658A1 (en) 2004-12-09
JP2011012072A (ja) 2011-01-20
JP2004359683A (ja) 2004-12-24
EP1484055B1 (de) 2009-11-04
ES2334664T3 (es) 2010-03-15
JP4629368B2 (ja) 2011-02-09

Similar Documents

Publication Publication Date Title
ATE447397T1 (de) Darreichungsform mit erhöhter bioverfügbarkeit
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
DK1157037T3 (da) GCSF-konjugater
EP1247456A3 (de) Wohlschmeckende pharmazeutische Zusammensetzung für Haustiere
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
WO2007043057A3 (en) Compositions for nasal delivery
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
WO2001043704A8 (en) A skin care composition that mediates cell to cell communication
EA200301275A1 (ru) Капсулы для ингаляции
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2008035020A3 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
EP1527770A3 (de) Kosmetische Maskenzusammensetzung
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
ATE301986T1 (de) Kosmetische stiftzubereitung
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
WO2004017943A3 (en) Non-vesicular cationic lipid formulations
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
UA90700C2 (ru) Оральная композиция немедленного выделения на основе слабоводорастворимого действующего вещества
SE0000303D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties